Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser microscope could spot urinary tract tumors without needles

NCT ID NCT02276924

Diagnosis Sponsor: Lille Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a laser confocal microscope, used during a kidney-ureter scope procedure, can tell the difference between normal and cancerous tissue in the upper urinary tract. 29 adults with conditions like blood in urine, kidney stones, or urinary tract cancer took part. The goal was to see if this imaging method could reduce the need for biopsies, which can be difficult and risky.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fluorescein (a dye used to highlight cells during imaging)
What this could lead to
If successful, this imaging technique could help doctors identify tumors during a scope procedure without taking tissue samples, making diagnosis safer and faster.
What could go wrong
This is a small, completed study with only 29 participants, so results may not apply to everyone. The technique is still experimental and may not be accurate enough to replace biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Oct 2013

Finished

Oct 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any legally adult fully informed patient who consent to participate to the study * Patient followed by the Urology Department * Indication for a diagnosis or treatment reno-ureteroscopy * Coverage of the social insurance Exclusion Criteria: * Minor Patient * Pregnancy or breast feeding * Concomitant treatment (for example beta-blocker) * Contra-indication to general anaesthesia * Hypersensitivity to sodium fluorescein * Medical history of cardio-pulmonary disease (myocardial infarction, cardiovascular event, bronchospasm ...) due to fluorescein instillation * Medical history of asthma or allergy due to fluorescein instillation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of urinary tract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm congenital anomalies of kidney and urinary tract 2 Hematuria Multicystic renal dysplasia, bilateral nephrolithiasis renal pelvis/ureter urothelial carcinoma urinary system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of urinary tract Hematuria Nephrolithiasis Ureteropelvic junction obstruction

Contacts and locations

Locations

  • Groupement des Hôpitaux de l'Institut Catholique de Lille

    Lille, Hauts-de-France, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.